The trajectory of Sildenafil presents a complex picture for those considering investment. While the initial introduction generated substantial returns, the lapse of its exclusive rights opened the floodgates to cheaper versions, dramatically diminishing sales. This poses a specific dilemma for pharmaceutical companies relying on related blockbuster

The story of Viagra, and its developer copyright, presents a challenging case study for investors. Originally a blockbuster drug, yielding billions in income, its patent expiration created a deluge of lower-priced alternatives , significantly diminishing its dominance. While specific pharmaceutical companies may try to capitalize on related treatme